GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » US Stem Cell Inc (OTCPK:USRM) » Definitions » Sale Of Investment

US Stem Cell (US Stem Cell) Sale Of Investment : $0.00 Mil (TTM As of Dec. 2022)


View and export this data going back to 2008. Start your Free Trial

What is US Stem Cell Sale Of Investment?

US Stem Cell's sale of investment for the three months ended in Dec. 2022 was $0.00 Mil. It means US Stem Cell gained $0.00 Mil from selling investments. US Stem Cell's sale of investment for the trailing twelve months (TTM) ended in Dec. 2022 was $0.00 Mil.

Compared with last quarter ($0.00 Mil in Sep. 2022 ), US Stem Cell gained the same money from selling investments in Dec. 2022 ($0.00 Mil).


US Stem Cell Sale Of Investment Historical Data

The historical data trend for US Stem Cell's Sale Of Investment can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

US Stem Cell Sale Of Investment Chart

US Stem Cell Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Sale Of Investment
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

US Stem Cell Quarterly Data
Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
Sale Of Investment Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

US Stem Cell Sale Of Investment Calculation

Sale of Investments represents cash inflow on the sale of investments in securities.

Sale Of Investment for the trailing twelve months (TTM) ended in Dec. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


US Stem Cell Sale Of Investment Related Terms

Thank you for viewing the detailed overview of US Stem Cell's Sale Of Investment provided by GuruFocus.com. Please click on the following links to see related term pages.


US Stem Cell (US Stem Cell) Business Description

Traded in Other Exchanges
N/A
Address
1560 Sawgrass Corporate Parkway, 4th Floor, Sunrise, FL, USA, 33323
US Stem Cell Inc is a biotechnology company engaged in the discovery and development of autologous cell therapies for the treatment of chronic and acute heart damage. Its product includes MyoCell, a clinical therapy designed to populate regions of scar tissue within a patient's heart with autologous muscle cells, or cells from a patient's body, for the purpose of improving cardiac function in chronic heart failure patients. The company's discoveries include multiple cell therapies in various stages of development that repair damaged tissues throughout the body due to injury or disease so that patients may return to a normal lifestyle.
Executives
Murphy William P Jr director 13794 NW 4TH STREET, SUITE 212, SUNRISE FL 33325
Gregory Knutson director 14855 ABERDEN STREET NE, HAM LAKE MN 55304
Mark P Borman director 5240 WASHBURN AVENUE SOUTH, MINNEAPOLIS MN 55410
Charles A Hart director 19345 RHINESTONE STREET NW, ANOKA MN 55303
Sheldon T. Anderson director 1121 CRANDON BLVD., APT. D-103, KEY BISCAYNE FL 33149
Kristin C Comella officer: Chief Science Officer 1310 LEEWARD WAY, WESTON FL 33327
A Jones Lee director 54 LOCKE LAKE RD, FRIDLEY MN 55432
Karl Groth director 1160 FIFTH AVENUE, SUITE 207, NEW YORK NY 10029
Matthew J Fendrich officer: Vice President,Sales&Marketing 482 PEACOCK LANE SOUTH, JUPITER FL 33458
Alan P Timmins director 1111 MAIN STREET, SUITE 600, VANCOUVER WA 98660
Bruce C Carson director 11850 COTTONWOOD STREET NW, COON RAPIDS MN 55448
Howard J Leonhardt director, 10 percent owner, officer: Executive Chairman & CTO 13794 NW 4TH STREET, SUITE 212, SUNRISE FL 33325
Bromley R Scott officer: VP of Public Relations 13794 NW 4TH STREET, SUITE 212, SUNRISE FL 33325
Richard Iii Spencer director 13794 NW 4TH STREET, SUITE 212, SUNRISE FL 33325
Mike Tomas director 13794 NW 4TH STREET, SUITE 212, SUNRISE FL 33325

US Stem Cell (US Stem Cell) Headlines

From GuruFocus

Corrected: USRM Posts Earnings for Second Quarter 2019

By PRNewswire PRNewswire 08-10-2019

USRM Oral Argument in Appeal from FDA Enforcement Action

By ACCESSWIRE ACCESSWIRE 01-19-2021

Northstar Biotech and USRM BOD Members Reinvest in the Company

By ACCESSWIRE ACCESSWIRE 02-23-2021

Dr. Kristin Comella Featured on Robert Scott Bell Show

By PRNewswire PRNewswire 11-09-2018

Court Reports Favorable Judgment in California Stem Cell Case

By ACCESSWIRE ACCESSWIRE 09-01-2022

USRM Posts Financial Results for First Quarter 2019

By PRNewswire PRNewswire 05-08-2019

Mark Borman Appointed Chairman of the Board of USRM

By ACCESSWIRE ACCESSWIRE 03-09-2022

USRM Posts 25% Nine Month Revenue Increase From 3Q 2017

By PRNewswire PRNewswire 11-08-2018